The Covid Era Tech Promises To Reinvent Cancer Treatment
Merck to Post 3Q Charge of About 28c/Share on Curon Deal >MRK
Express News | Merck & Co Inc - Recording Pre-Tax Charge of $750 Million, or $0.28 per Share
Express News | Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, Cn201, From Curon Biopharmaceutical
Merck & Co., Inc. (MRK) Projects 21% Upside With $140 Price Target as Keytruda and New Vaccines Drive Growth
Stocks With the Highest Consensus of Expected ROE Growth, Goldman Sachs Says
Merck & Co., Inc. (NYSE:MRK) Is a Favorite Amongst Institutional Investors Who Own 79%
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
Merck Snaps Six Straight Sessions of Losses
Merck & Co., Inc. (MRK): An Undervalued Wide Moat Stock to Buy According to Analysts
Express News | Merck: Will Continue Discussions With FDA to Help Enable Continued Access to Keytruda for Appropriate Patients
Express News | Merck Provides Update on Fda’s Oncologic Drugs Advisory Committee Meeting Discussion of Pd-L1 Expression Levels in Certain Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer Indications
Merck, Bristol-Myers Fail to Convince FDA AdCom on Wider Opdivo, Keytruda Use
Is Merck & Co., Inc. (MRK) the Best Cheap Beginner Stock to Invest In?
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
Evaxion Stock Jumps on Expanded Vaccine Development Pact With MSD
Evaxion Biotech Has Entered Into An Option And License Agreement With Merck For Two Preclinical Vaccine Candidates, For An Upfront Payment Of $3.2M And Up To $10M In 2025, If Merck Exercises Its Option To License Either One Or Both Candidates And...
Merck Announced That New Data Highlighting The Long-term Efficacy And Safety Of Tulisokibart (MK-7240) In Ulcerative Colitis And Crohn's Disease Will Be Presented At The United European Gastroenterology Week 2024 Congress
Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $142
Merck & Co. Inc. (MRK): A Good Undervalued Blue Chip Stock to Buy According to Analysts